萘基并2,1-d啶-4-胺類衍生物的合成

萘基并2,1-d啶-4-胺類衍生物的合成

含有吡啶和吡啶的化合物具有多種藥理活性。作為重要的生物分子dna（異丙醇吡啶）和磷酸酯（異丙醇吡啶）的結構單元，受到藥物化學工作者的高度重視。二羥色胺、三氟吡啶、二羥色胺、二羥色胺、二氯丁基吡啶和環(huán)磷酰胺的三維結構。作為二羥色胺、二羥色胺、丙烯酸酯和蛋白醇的抗劑劑，已被證明對抗炎和抗癌藥物以及亞硝酸和心腦血管疾病的治療。近年來,由于4-氨基嘧啶并環(huán)類化合物,如4-氨基喹唑啉、4-氨基吡啶并嘧啶、4-氨基吡咯并嘧啶、4-氨基噻吩并嘧啶等,在抗菌、消炎、抗高血壓、抗癌等治療中表現(xiàn)出良好的生物活性,因此,4-氨基嘧啶并環(huán)類化合物的合成,在藥物合成研究領域中日益受到人們的關注.薁為含有雙環(huán)結構的非苯芳烴化合物,是萘的同分異構體,具有靚麗的色彩,表現(xiàn)出獨特的物理、化學特性.薁類衍生物具有廣泛的生物活性,表現(xiàn)出良好的抗?jié)儭⒖拱?、抗氧?以及除草、殺蟲、殺菌等活性,在醫(yī)藥和農(nóng)藥領域中得到廣泛應用.在薁類化學的研究中,我們曾以2-甲基薁、1-乙?；牎?-氯乙?；牶?-甲?；牭茸鳛楹铣勺雍铣闪诵滦褪狀惓黼s環(huán)化合物.為進一步研究雜環(huán)修飾的薁類衍生物的合成及其生物活性,我們以2-氨基-3-氰基薁-3-甲酸甲酯為反應底物合成了薁并[2,1-d]嘧啶類衍生物,為進一步擴大該方法的應用范圍及考察此類分子的多樣性,本文以托酚酮、萘乙酸乙酯、N,N-二甲基甲酰胺二甲縮醛(DMF-DMA)及芳香胺為原料,進行新型薁類稠雜環(huán)化合物的合成方法研究.經(jīng)過氯代、縮合、環(huán)加成、環(huán)化反應構建了萘基薁并[2,1-d]嘧啶-4-胺類衍生物,合成路線如Scheme1所示.1實驗部分1.1紅外光譜測定熔點用WRS-1B數(shù)字熔點儀測定,熔點未校正;NMR用BrukerDPX-300MHz核磁共振儀測定,四甲基硅烷為內(nèi)標;IR用BIO-RADFTS-40型傅立葉變換紅外分光光度計測定,KBr壓片;MS采用ZAB-HS型質(zhì)譜儀測定;元素分析用VarioEL元素分析儀測定.所用試劑均為分析純或按照文獻方法合成.1.22-氨基-3-萘基3的合成1.2.12-氯環(huán)庚三烯醚制備1以托酚酮為原料,經(jīng)氯化亞砜氯化制備,收率88%,m.p.161～163℃.1.2.2環(huán)戊三烯[b]呋喃-2-酮衍生物3a2m將2-氯環(huán)庚三烯酮(20.0mmol)與1-萘乙酸乙酯(2a)或2-萘乙酸乙酯(2b)(40.0mmol)溶于無水乙醇(100mL)中,冰-水冷卻下,滴入乙醇鈉的乙醇溶液[由金屬鈉(40.0mmol)和無水乙醇(50mL)制得],用硅膠層析板(TLC)監(jiān)控反應.反應完畢后,減壓蒸出溶劑,得到殘余物轉(zhuǎn)入冰水中,用10%的鹽酸調(diào)至中性,乙酸乙酯提取(50mL×2),無水硫酸鈉干燥,濃縮、通過硅膠柱分離(硅膠:160～200目;乙酸乙酯/正己烷(V∶V=4∶1)為洗脫劑),得到相應的環(huán)庚三烯[b]呋喃-2-酮衍生物2.3-(1-萘基)環(huán)庚三烯[b]呋喃-2-酮(2a):收率87%,紅色針狀結晶.m.p.93～95℃;1HNMR(CDCl3,300MHz)δ:7.08～7.28(m,3H),7.35(dd,J=9.6,9.6Hz,1H),7.52～7.55(m,4H),7.71(dd,J=9.6,10.0Hz,1H),7.90～8.02(m,2H),8.25(d,J=10.0Hz,1H);IR(KBr)ν:1673(C=O)cm-1;EMSm/z:273(M++1).Anal.calcdforC19H12O2:C83.81,H4.44;foundC83.95,H4.56.3-(2-萘基)環(huán)庚三烯[b]呋喃-2-酮(2b):收率80%,紅色針狀結晶.m.p.96～97℃;1HNMR(CDCl3,300MHz)δ:7.15～7.31(m,3H),7.39(dd,J=9.6,9.6Hz,1H),7.46～7.58(m,4H),7.75(dd,J=9.6,9.6Hz,1H),7.94～8.09(m,2H),8.21(d,J=10.0Hz,1H);IR(KBr)ν:1683(C=O)cm-1;EMSm/z:273(M++1).Anal.calcdforC19H12O2:C83.81,H4.44;foundC83.99,H4.62.1.2.3化合物3a3e,3a3e,3a3e,3a3e,3a3,3e,3a3,3e,3a3,3e,3a3,3e,3a3,3e,3e,3e,3e,3e,3a3,3e,3a3,3a3,3a3,3e,3a3,3e,3e,3a3,3a3,3a3,3e,3a3,3a3,3a3,3a3,3a3,3a3,3a3,3a3,3a3,3a3,3a3,3a3,3a3e,3a3e,3a3e,3a3e,3a3e,3a3e,3a3e,3a3e,3a3e,3a3e,3a3e,3a3e,3a3e,3a3e,3a3e,3a3e,3a3e,3a3e,3a3e,3a3e,3e,3e,3e,3e,3e,3e,3e,3a3,3a3,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3a3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,3e,將3-萘基環(huán)庚三烯并呋喃-2-酮(2a)(10.0mmol)、丙二腈(20.0mmol)溶于無水乙醇(50mL)中,緩慢滴入三乙胺(5mL),室溫攪拌.用硅膠層析板(TLC)監(jiān)控反應.反應完畢后(約2h),減壓蒸出溶劑,得到殘余物轉(zhuǎn)入水(100mL)中,用10%的鹽酸調(diào)至中性,乙酸乙酯提取(40mL×2),無水硫酸鈉干燥,濃縮、通過硅膠柱分離[硅膠:160～200目;乙酸乙酯/正己烷(V∶V=3∶1)為洗脫劑],得到相應的2-氨基-1-氰基-3-萘基薁衍生物3.2-氨基-1-氰基-3-(1-萘基)薁(3a):收率92%,桔紅色針狀結晶.m.p.102～105℃;1HNMR(CDCl3,300MHz)δ:7.39～7.41(m,2H),7.48～7.53(m,3H),7.57～7.65(m,3H),7.84(dd,J=9.6,10.0Hz,1H),8.26～8.29(m,1H),8.37(d,J=10.0Hz,1H),8.73(d,J=9.6Hz,1H);IR(KBr)ν:3435(NH2),2228(CN)cm-1;EMSm/z:295(M++1).Anal.calcdforC21H14N2:C85.69,H4.79,N9.52;foundC85.75,H4.93,N9.71.2-氨基-1-氰基-3-(2-萘基)薁(3b):收率88%,桔紅色針狀結晶.m.p.104～105℃;1HNMR(CDCl3,300MHz)δ:4.96(s,NH2,2H),7.20(dd,J=9.6,9.6Hz,1H),7.41～7.45(m,3H),7.49～7.56(m,3H),7.59～7.67(m,2H),7.99～8.01(m,2H),8.21(d,J=8.8Hz,1H);IR(KBr)ν:3422(NH2),2212(CN)cm-1;EMSm/z:295(M++1).Anal.calcdforC21H14N2:C85.69,H4.79,N9.52;foundC85.82,H4.86,N9.64.1.31nmr-a型將2-氨基-1-氰基-3-萘基薁(3)(10.0mmol)溶于苯(50mL)中,加入N,N-二甲基甲酰胺二甲縮醛(DMF-DMA)(20.0mmol),加熱回流5h.冷卻至室溫后,蒸出溶劑,加入水(20mL),用乙酸乙酯(50mL×2)提取,分出有機相,無水硫酸鈉干燥,蒸出溶劑,得到殘余物通過硅膠柱分離[硅膠:160～200目;乙酸乙酯/正己烷(V∶V=4∶1)為洗脫劑],得到相應的1-氰基-2-N,N-二甲基脒基薁衍生物(4).1-氰基-2-N,N-二甲基脒基-3-(1-萘基)薁(4a):收率85%,褐色針狀結晶.m.p.105～107℃;1HNMR(CDCl3,300MHz)δ:2.76(s,NCH3,3H),3.01(s,NCH3,3H),5.29(s,1H),7.20(dd,J=9.6,9.6Hz,1H),7.37(dd,J=9.2,9.6Hz,1H),7.45～7.50(m,3H),7.55～7.58(m,4H),7.81(d,J=10.0Hz,1H),7.93(d,J=8.8Hz,1H),8.43(d,J=9.6Hz,1H);IR(KBr)ν:2205(CN)cm-1;EMSm/z:350(M++1).Anal.calcdforC24H19N3:C82.49,H5.48,N12.03;foundC82.53,H5.64,N12.21.1-氰基-2-N,N-二甲基脒基-3-(2-萘基)薁(4b):收率78%,褐色針狀結晶.m.p.116～118℃;1HNMR(CDCl3,300MHz)δ:2.75(s,3H),2.95(s,3H),5.29(s,1H),7.21(dd,J=9.6,9.6Hz,1H),7.38(dd,J=9.2,9.6Hz,1H),7.46～7.53(m,3H),7.57～7.59(m,3H),7.68(s,1H),7.89(d,J=10.0Hz,1H),7.92(d,J=8.2Hz,1H),8.41(d,J=9.6Hz,1H);IR(KBr)ν:2207(CN)cm-1;EMSm/z:350(M++1).Anal.calcdforC24H19N3:C82.49,H5.48,N12.03;foundC82.65,H5.52,N12.18.1.4n-4-甲基苯基-10-1--2,1-d]吡啶-4-胺5c的合成將1-氰基-2-N,N-二甲基脒基薁(4)(5.0mmol)溶于冰乙酸(40mL)中,加入芳香胺(5)(10.0mmol),加熱,保持反應溫度在80℃.用硅膠層析板(TLC)監(jiān)控反應.反應完畢后,將混合物轉(zhuǎn)入水(100mL)中,用15%KOH溶液調(diào)節(jié)pH至9～10.用乙酸乙酯(50mL×2)提取,分出有機相,無水硫酸鈉干燥,濃縮、得到殘余物通過硅膠柱分離[硅膠:160～200目;乙酸乙酯-正己烷(V∶V=5∶1)為洗脫劑],得到相應的N-萘基薁并[2,1-d]嘧啶-4-胺類衍生物6a～6j.N-(4-苯基)-10-(1-萘基)薁并[2,1-d]嘧啶-4-胺(6a):收率76%,棕色針狀結晶.m.p.70～72℃;1HNMR(CDCl3,300MHz)δ:7.26～7.30(m,2H),7.37(s,1H),7.45～7.50(m,3H),7.62～7.69(m,5H),7.75～7.79(m,3H),7.99～8.02(m,3H),8.33(brs,1H),9.03(d,J=8.4Hz,1H);IR(KBr)ν:3426(NH)cm-1.Anal.calcdforC28H19N3:C84.61,H4.82,N10.57;foundC84.72,H4.74,N10.71.N-(4-甲基苯基)-10-(1-萘基)薁并[2,1-d]嘧啶-4-胺(6b):收率80%,棕色針狀結晶.m.p.205～207℃;1HNMR(CDCl3,300MHz)δ:2.05(s,3H),7.08(dd,J=8.2,8.8Hz,1H),7.21～7.27(m,3H),7.39(s,1H),7.43～7.46(m,3H),7.51～7.58(m,5H),7.88～7.91(m,3H),8.52(brs,1H),9.05(d,J=8.8Hz,1H);IR(KBr)ν:3421(NH)cm-1.Anal.calcdforC29H21N3:C84.61,H4.82,N10.57;foundC84.64,H5.14,N10.21.N-(3-甲氧基苯基)-10-(1-萘基)薁并[2,1-d]嘧啶-4-胺(6c):收率84%,棕色針狀結晶.m.p.104～106℃;1HNMR(CDCl3,300MHz)δ:4.18(s,3H),7.17(dd,J=8.8,9.6Hz,1H),7.23～7.28(m,3H),7.37(s,1H),7.49(s,1H),7.63～7.75(m,6H),8.04～8.10(m,4H),8.79(brs,1H),8.85(d,J=8.4Hz,1H);IR(KBr)ν:3418(NH)cm-1.Anal.calcdforC29H21N3O:C81.48,H4.95,N9.83;foundC81.63,H5.16,N9.78.N-(4-氯苯基)-10-(1-萘基)薁并[2,1-d]嘧啶-4-胺(6d):收率74%,棕色針狀結晶.m.p.189～191℃;1HNMR(CDCl3,300MHz)δ:7.34～7.36(m,4H),7.42(s,1H),7.59～7.64(m,6H),7.95～8.07(m,5H),8.75(brs,1H),9.20(d,J=8.8Hz,1H);IR(KBr)ν:3426(NH)cm-1.Anal.calcdforC28H18ClN3:C77.86,H4.20,N9.73;foundC77.92,H4.36,N9.87.N-(4-氟苯基)-10-(1-萘基)薁并[2,1-d]嘧啶-4-胺(6e):收率79%,棕色針狀結晶.m.p.226～228℃;1HNMR(CDCl3,300MHz)δ:6.96～7.00(m,2H),7.28～7.30(m,2H),7.37(s,1H),7.49～7.52(m,3H),7.69～7.71(m,4H),7.84～7.88(m,4H),8.16(brs,1H),9.49(d,J=8.6Hz,1H);IR(KBr)ν:3413(NH)cm-1.Anal.calcdforC28H18FN3:C80.95,H4.37,N10.11;foundC81.24,H4.49,N9.96.N-(4-氟-3-甲基苯基)-10-(1-萘基)薁并[2,1-d]嘧啶-4-胺(6f):收率75%,棕色針狀結晶.m.p.220～222℃;1HNMR(CDCl3,300MHz)δ:2.50(s,3H),6.97～7.03(m,1H),7.16～7.18(m,2H),7.38(s,1H),7.49～7.51(m,3H),7.57～7.65(m,4H),7.69(s,1H),8.01～8.06(m,3H),8.24(brs,1H),9.04(d,J=8.6Hz,1H);IR(KBr)ν:3418(NH)cm-1.Anal.calcdforC29H20FN3:C81.10,H4.69,N9.78;foundC81.32,H4.86,N9.89.N-(4-苯基)-10-(2-萘基)薁并[2,1-d]嘧啶-4-胺(6g):收率73%,棕色針狀結晶.m.p.113～115℃;1HNMR(CDCl3,300MHz)δ:7.19～7.22(m,2H),7.31(s,1H),7.39～7.43(m,3H),7.57～7.62(m,5H),7.74～7.77(m,3H),7.94～8.09(m,3H),8.35(brs,1H),9.21(d,J=8.8Hz,1H);IR(KBr)ν:3419(NH)cm-1.Anal.calcdforC28H19N3:C84.61,H4.82,N10.57;foundC84.69,H4.91,N10.64.N-(4-甲基苯基)-10-(2-萘基)薁并[2,1-d]嘧啶-4-胺(6h):收率76%,棕色針狀結晶.m.p.174～176℃;1HNMR(CDCl3,300MHz)δ:2.05(s,3H),7.08(dd,J=8.4,8.8Hz,1H),7.22～7.26(m,3H),7.38(s,1H),7.42～7.48(m,3H),7.54～7.60(m,5H),7.89～7.93(m,3H),8.58(brs,1H),8.89(d,J=8.8Hz,1H);IR(KBr)ν:3424(NH)cm-1.Anal.calcdforC29H21N3:C84.61,H4.82,N10.57;foundC84.75,H4.93,N10.64.N-(4-甲氧基苯基)-10-(2-萘基)薁并[2,1-d]嘧啶-4-胺(6i):收率79%,棕色針狀結晶.m.p.79～81℃;1HNMR(CDCl3,300MHz)δ:3.94(s,3H),7.04(dd,J=8.8Hz,1H),7.23～7.27(m,2H),7.38(s,1H),7.54～7.62(m,2H),7.63～7.69(m,6H),7.97～8.01(m,4H),8.51(brs,1H),8.94(d,J=8.8Hz,1H);IR(KBr)ν:3421(NH)cm-1.Anal.calcdforC29H21N3O:C81.48,H4.95,N9.83;foundC81.57,H5.14,N9.72.N-(4-氯苯基)-10-(2-萘基)薁并[2,1-d]嘧啶-4-胺(6j):收率74%,棕色針狀結晶.m.p.133～135℃;1HNMR(CDCl3,300MHz)δ:7.26～7.33(m,4H),7.45(s,1H),7.60(s,1H),7.68～7.73(m,5H),7.85～7.90(m,4H),7.96(d,J=8.0Hz,1H),8.73(brs,1H),9.18(d,J=8.8Hz,1H);IR(KBr)ν:3429(NH)c